Amyloid Therapy Program
Hartford HealthCare offers a coordinated, systemwide program to support referring providers considering anti-amyloid monoclonal antibody therapy for patients with Alzheimer’s disease.
Given the need for careful patient selection and monitoring, our structured approach streamlines evaluation and provides clear, multidisciplinary guidance.
Multidisciplinary Evaluation
Because anti-amyloid therapies carry important risks, careful patient selection is essential. To support this process, we have an anti‑amyloid therapy board composed of experts from multiple disciplines, including
- Neurology
- Geriatrics
- Neuropsychiatry
- Nuclear Medicine and MRI
- Pharmacy
- Infusion Nursing
- Social Work
This team-based review ensures evidence-based assessment, appropriate candidacy determination and coordinated treatment planning.
Amyloid Therapy Board
For complex or borderline cases, referring providers may request review by our multidisciplinary Amyloid Therapy Board (ATB).
Providers may:
- Submit a case for formal review
- Present the case directly or request presentation by an ATB member
- Receive a coordinated recommendation to help guide clinical decision-making
The ATB supports shared decision-making and promotes consistent, systemwide standards for patient selection and safety.
Nurse Navigator Support
A dedicated nurse navigator assists with:
- Eligibility clarification
- Required testing coordination
- Referral triage and scheduling
This support is available whether you are evaluating a specific patient or seeking guidance on program criteria.
Safety and Monitoring
Anti-amyloid therapies carry known risks, including amyloid-related imaging abnormalities (ARIA). Our program includes structured MRI monitoring protocols and coordinated follow-up to support safe treatment administration.